Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.74 |
| ▸ | ESRRG | P62508 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | ESRRB | O95718 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | PLD2 | O14939 | 1/20 | 0.74 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miproxifene SCHEMBL409027 | 0.99 | ESR1 (0.76) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL34173 | 0.99 | ESR1 (0.76) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL409028 | 0.99 | ESR1 (0.76) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857612 | 0.98 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857619 | 0.98 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857626 | 0.98 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL3781209 | 0.93 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL430163 | 0.93 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL3781215 | 0.93 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL9857240 | 0.90 | ESR1 (0.90) | ESR1ESR2ESRRGMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | claimed |
| EP-2582371-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | Endorecherche, Inc. (CA) | 2013-04-24 | — | — | EP | disclosed |
| EP-2442807-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Endorecherche, Inc. (CA) | 2012-04-25 | — | — | EP | disclosed |
| WO-2011156908-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | ENDORECHERCHE, INC. (CA) | 2011-12-22 | — | — | WO | disclosed |
| WO-2010145010-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ENDORECHERCHE, INC. (CA) | 2010-12-23 | — | — | WO | disclosed |
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | disclosed |
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2002-12-26 | — | — | US | disclosed |
| EP-1251855-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | Endorecherche, Inc. (CA) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001054699-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | ENDORECHERCHE, INC. (CA) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | ESR1 2/4885ESR2 8/4885ESRRG 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.